INTRODUCTION

Cancer is a group of diseases that cause cells throughout the body to change and grow out of control. Most types of cancer cells eventually form a lump or mass called a tumor, and are named after the part from the body where the tumor originates. Cancer is one of the leading causes of death worldwide, which has been attributed to many factors that have influenced the increase on the number of cases. Some of the direct factors include the growth as the population, aging, and adoption of lifestyle behaviors that are known to cause cancer [1]. According to world health organization, more than 57 million deaths have occurred in 2008. Of which, 36 million (63%) deaths were due to non-communicable diseases such as cardiovascular diseases, diabetes and cancer [2]. Of all non-communicable diseases, with more than 7.6 million deaths, cancer ranked third as the leading cause of death worldwide. The current statistics suggest that the cancer prevalence will continue to rise and may reach around 17 million cancer deaths by 2030 [3, 4]. The major therapeutic approaches to the treatment of both localized and metastasized cancer in chemotherapy, which are being used alone or in a combination of other forms of cancer therapies [5]. However, the use of chemotherapeutic drugs is limited by high toxicity, rapid elimination from the systemic circulation, accumulation in non-targeted organs and tissues, enzymatic and hydrolytic degradation and/or inefficient cell entry. Thus, the inhibition of tumor cell growth without side effects is recognized as an important target for cancer therapy. Dietary flavonoids are a widely distributed group of diphenolic compounds of plant origin. Epidemiological studies have consistently shown an inverse association between consumption of some nutritional flavonoids and the risk of human cancers at many sites [6-9]. NAR has been widely studied and has been reported to be an antioxidant [10, 11], NAR, and the aglycone of naringin was found to exhibit aorta anti-ulcer effects [12], antioxidant [13] and dilatory as well as inhibiting the proliferation of breast cancer and delaying mammary tumorigenesis. Fig. (1) Shows the chemical structure of naringenin [14].

Fig. 1: Chemical structure NAR

Regrettfully, the clinical relevance of NAR is limited by its low solubility and minimal bioavailability owing to its largely hydrophobic ring structure. In addition, NAR had unfavourable body distribution and inability to cross-cellular barriers. Therefore NARNS was developed to overcome major obstacles associated with NAR bioavailability. One of the ways to improve the selectivity and effectiveness of nanoparticle delivery system is by conjugating nanoparticles to molecules that could specifically reach target cancer cells [15]. Nanotechnology is the control as a matter at
The homogenized nanosuspensions were freeze-dried to increase the shelf life of suspension and to study the dissolution behaviour. 1% mannitol was added to each formulation as a cryoprotectant at the time of lyophilization. Virtis freeze drier is used for lyophilization of nanosuspension. At first, the sample was kept overnight in deep freezer at -70 °C and then the sample was kept in Virtis freeze drier for two days at 50 °C at 2 millitorr [21].

Particle size distribution and polydispersity index

The particle size analysis of different batches of nanosuspension was carried out using Microtac Blue wave-particle size analyzer. Before measurement of the samples, they have to be diluted with de-ionized water to obtain a suitable concentration for measurement. The results obtained for particle size distributions were used to confirm the formation of nano-sized particles [22].

Zeta potential analysis

The particle charge was one of the most important parameters in assessing the physical stability of emulsion and suspensions. The large numbers of particles were equally charged; then electrostatic repulsion between the particles was increased, and thereby physical stability of the formulation was also increased. Typically, the particle charge of the colloidal system was measured as zeta potential via the electrophoretic mobility of the particles in an electrical field. Zeta potential analysis of prepared nanosuspension formulation was carried out using Malvern Zetasizer (Malvern Instruments). Before measurement, the samples were diluted with de-ionized water, and conductivity was adjusted by addition of sodium chloride [22].

Re-dispersibility and percentage drug content determination

The NARNS were analyzed for drug content by UV spectroscopic method. Different batches of nanosuspension equivalent to 10 mg of NAR weighed accurately and dissolved in 10 ml methanol. The stock solutions were diluted with distilled water and analyzed by UV spectroscopy at 290 nm [23].

Determination of entrapment efficiency (EE) of nanosuspension

10 ml of nanosuspension was centrifuged at 5000 rpm for 20 min. The supernatant solution was filtered and separated. One ml of these filtrates was diluted with water and the absorbance at maximum λ max was measured by UV spectrophotometer using water as blank [24]. The amount of free drugs in the formulations was measured and the entrapment efficiency is then calculated.

Saturation solubility studies

The saturation solubility studies were carried out for both the unprocessed pure drug and different batches of lyophilized nanosuspension. 10 mg of unprocessed pure drug and nanosuspension equivalent to 10 mg of NAR was weighed and separately introduced into 25 ml stopper conical flask containing 0.1 N HCl pH 1.2 to prepare 0.1 mg/ml stock solution for each medium. The prepared samples were analyzed spectrophotometrically at λ max in these media. The plot of absorbance vs. concentration is done and beer's range was determined [18]. The results were analyzed in triplicate, and the standard deviation was represented.

Fourier transform Infra-red spectroscopy

FT-IR spectra were recorded in the sample prepared in KBr disks (2 mg sample in 200 mg KBr disks) using Shimadzu Fourier Transform Infra-Red spectrometer. The samples were scanned over a frequency range 4000-400 cm⁻¹ [19].

Formulation of naingnin nanosuspension

NARNS was prepared by high pressure homogenization technique by using the different concentration of the stabilizers like Soya lecithin (N1 and N2) poloxamer 407 (N3 and N4), poloxamer 188 (N5 and N6), Hydroxypropyl methyl cellulose (HPMC) (N7 and N8) and Tween-80 (N9 and N10) with (0.75 % and 1.5 %) and TPGS (1%) respectively, but in all the drug concentration remains constant. NAR powder (1 % w/v) was dispersed in aqueous surfactant solution using magnetic stirrer. After drug dispersion in the surfactant solution first size reduction step was carried out using an Ultra-Turax T25 basic homogenizer at 9500 rpm for 10 min. The obtained mixtures were homogenized using Micron-LAB 40 high-pressure homogenizer, the homogenization step includes first two cycles at 100 bar and next two cycles at 500 bars pressure as an initial step. Finally, the suspension was homogenized for 15 cycles at 1500 bar pressure [20].

Table 1: Composition of NARNS

| Code | Drug: Polymer: TPGS ratio |
|------|--------------------------|
| N1   | 1:0.75:1 (Nar: Soya lecithin: TPGS) |
| N2   | 1:1.5:1 (Nar: Soya lecithin: TPGS) |
| N3   | 1:0.75:1 (Nar: Polaxamer407: TPGS) |
| N4   | 1:1.5:1 (Nar: Poloxamer407: TPGS) |
| N5   | 1:0.75:3 (Nar: Poloxamer188: TPGS) |
| N6   | 1:1.5:1 (Nar: Poloxamer188: TPGS) |
| N7   | 1:0.75:1 (Nar: HPMC: TPGS) |
| N8   | 1:1.5:1 (Nar: HPMC: TPGS) |
| N9   | 1:0.75:1 (Nar: Tween-80: TPGS) |
| N10  | 1:1.5:1 (Nar: Tween-80: TPGS) |
ml distilled water. The flasks were sealed and placed in rotary shaker for 24 h at 37 °C and equivalent for 2 d. The samples were collected after the specified time interval, and it is filtered and analyzed. The samples were analyzed using UV spectrophotometer at 290 nm [25].

**In vitro drug release studies**

The in vitro release of NAR drug and its NARNS were carried out in USP dissolution test apparatus using paddle method at a rotation speed of 50 rpm. The dissolution profile was carried out in the freshly prepared acidic buffer (pH 1.2) and also in the phosphate buffer (pH 7.4). 10 mg of pure drug and nanosuspension containing 10 mg of naringenin equivalent was taken and placed in the dissolution mediums. The volume and temperature of dissolution medium were 900 ml and 37.0±0.2 °C, respectively. Samples were withdrawn at fixed time intervals and were filtered. The filtered samples were analyzed at 290 nm using Shimadzu UV-Visible spectrophotometer. The results obtained for different batches of the formulation were compared to the dissolution profile of NAR [25, 26].

**In vitro permeation studies**

Permeation study was carried out for both unprocessed drug and different batches of nanosuspension using cellulose nitrate membrane. The membrane was attached to the diffusion cell, and then it was dipped in a beaker containing phosphate buffer pH 7.4. The pure drug sample and equivalent quantities of lyophilized nanosuspension were weighed and placed in the different diffusion cell containing the specific quantity of buffer. The samples were withdrawn at specific time intervals for 1 hr and replaced with fresh buffer solution. Finally, the samples were analyzed using UV spectrophotometer at 290 nm [27].

**Differential scanning calorimetry**

Thermal properties of formulations were analyzed by differential scanning calorimetric analysis using Toledo-DSC II. To characterize the changes in internal structure DSC analysis was carried out for NAR, polymer and the lyophilized NARNS. The 5 mg of sample was taken in the aluminum vial and kept in the instrument. The sample was then heated from 20 °C to 200 °C at a heating rate of 10 °C/min under a stream of nitrogen at a flow rate of 50 ml/min. Enthalpy changes (ΔH) were calculated peak to study the polymeric changes (ΔH) were calculated peak to study the changes (ΔH) were calculated peak to study the changes of the formulations [28].

**Scanning electron microscopy**

The scanning electron microscopy (SEM) is one of the most important instruments used for analysis of surface morphology. The particle size analysis of lyophilized NARNS was carried out to confirm the nanosized of the formulation. The samples are lightly sprinkled on a double side adhesive tape stuck to an aluminium stub, and the subs were coated with platinum. The stub containing sample is placed in SEM chamber and analyses the surface morphology [29].

**Powder X-ray diffraction pattern**

The P-XRD studies of nanosuspension were carried out using X-ray diffractometer with copper (Cu) as target filter having a voltage/current of 40KV/40 Ma at a scan speed of 1 °/min. The samples were analyzed at a 2θ angle range of 5-70° [30, 31].

**Stability study**

Stability studies were carried out for naringenin nanosuspension formulation as per ICH guidelines. The best NARNS (N2) was sealed in high-density polyethylene bottles and stored at 4±1 °C/Ambient, 25±2 °C/60±5 % RH, 40±2 °C/75±5 % RH for 90 d. The samples were evaluated for percentage naringenin nanosuspension. [32].

**Hemocompatibility assessment**

**Whole blood cell lysis**

Blood was collected in heparinized tubes from Wistar rats and centrifuged for 10 min at 800g at 4 °C. The cell pellet was resuspended in 0.9% NaCl solution in order to prepare a 2 % (v/v) cell suspension. One hundred µl of this suspension were plated in each well of a 96-well round bottom plate. The formulated nanosuspension (NF2) solutions of different concentrations (3.90-500 µg/ml) in 0.9% (w/v) in NaCl were added to the plate and incubated for 1 h and 24 h at 37 °C in 5 % CO₂. The release of haemoglobin, as an index of red blood cell (RBC) lysis (haemolysis), was determined by spectrophotometric analysis of the supernatant at 570 nm. Complete haemolysis (positive control) was achieved by adding 1% (v/v) Triton X-100, while cells in 0.9 % (w/v) NaCl solution served as negative control [33, 34].

**Statistical analysis**

The results were expressed as mean±SD and were analyzed statistically by one-way analysis of variance (ANOVA) using Graph Pad Prism V5.04 software at the level of significance (p<0.05).

**RESULTS AND DISCUSSION**

**Determination of λ Max**

The analysis of UV spectra of naringenin in, HC l buffer pH 1.2 and Phosphate buffer pH 7.4 shows the same λ max 290 nm which similar to the published one as shown in fig. 1. A and 1. B [34].
Zeta potential

Zeta potential gives certain information on the surface charge properties and further the long-term physical stability of the nanosuspension. The zeta potential for the ten formulations of NARNS was shown in fig. 4. The charge was negative due to adsorbed stabilizer and TPGS on the drug particles; so, negative zeta potential is attributed to drug nanosuspension. In general, zeta potential values of ±20 mV are sufficient for the stability of nanosuspension stabilized by the stearic stabilizer. The selected polymers indicating that the prepared formulation would not suffer from instability problems.

The effect of particle size and polydispersity index (PDI) was studied using ten different formulations. All the prepared formulations were in the nano size. The mean particle size (effective diameter) for formulations varied in the narrow range from 70.89±0.0 nm to 144.5±0.0 nm. The particle size and PDI for different formulations are showing in table 2. The choice of suitable stabilizers and its concentration are the most important factors to control the size and stability of our work; Soya lecithin, Poloxamer-407, Poloxamr-188, HPMC, and Tween-80 were used at a different concentration (table 1). The optimum concentration was in the formulation of N1, N2 and N3, which has particle size 74.37±0.16, 80.52±0.13 and 70.89±0.21 nm. Also, these formulation shows PDI in the range of 0.327±0.05, 0.284±0.01 and 0.293±0.09 and this low value will indicate good stability of the nanosuspension. The results showed that PDI is reduced with the increasing of stabilizer concentration as the PDI of formula N1 contains 1:0.75:1 of drug (NAR: Soya lecithin: TPGS) ratio was 0.327±0.05 nm compared with 0.284±0.01 nm for N2 which contains 1:1.5:1 ratio of drug: stabilizer: Co-stabilizer. The reason behind this is that high stabilizer concentration decreases surface tension and stabilizes newly developed surfaces during high-pressure homogenization process and produce nanosuspension of less PDI [35]. Furthermore, low or insufficient concentration of stabilizer will cause instability and recrystallization. TPGS has been shown to improve the bioavailability of many compounds [36]. The combination of TPGS and HPMC in the nanosuspension formulation was shown to inhibit the crystal growth within the system [37]. This could be attributed to the increase in the molar substitution ratio (MSR) of the polymer per drug. The increase of the hydrophilic corona surrounding the polymer to protect the nanosuspension enhances the stability and prevents particles from aggregation. The PDI values were ranged from 0.284±0.05-0.595±0.16, which indicate the acceptable uniformity level for all the prepared formulations [38]. Narrower range of particles sizes will minimize the difference between active agent concentration and the surrounding environment. As a result, the Ostwald ripening phenomenon will be inhibited in nanosuspension during high-pressure homogenization methods [39, 40].
Table 2: Particle size, polydispersity index, zeta potential, drug content and drug entrapment efficiency of naringenin nanosuspension

| S. No | Formulations | Average particle size (d. nm) | Poly dispersity index (PDI) | Zeta potential (mV) | Drug content | Drug entrapment efficiency (%) |
|-------|--------------|-------------------------------|-----------------------------|---------------------|--------------|---------------------------------|
| 1.    | N1           | 74.37±0.16                    | 0.327±0.05                  | 1.86                | 95.49±0.63   | 89.0±0.23                       |
| 2.    | N2           | 80.52±0.13                    | 0.284±0.01                  | -26.9               | 98.61±0.32   | 94.75±0.62                      |
| 3.    | N3           | 70.89±0.21                    | 0.293±0.09                  | -13.1               | 94.73±0.12   | 88.26±0.86                      |
| 4.    | N4           | 95.94±0.16                    | 0.359±0.09                  | -22.5               | 95.00±0.61   | 90.12±0.48                      |
| 5.    | N5           | 100.6±0.28                    | 0.265±0.21                  | -9.56               | 91.34±0.56   | 80.45±0.01                      |
| 6.    | N6           | 106.3±0.21                    | 0.595±0.16                  | -16.6               | 93.49±0.10   | 84.0±0.49                       |
| 7.    | N7           | 129.0±0.13                    | 0.422±0.26                  | -1.67               | 89.45±0.28   | 78.56±0.72                      |
| 8.    | N8           | 110.7±0.64                    | 0.318±0.21                  | -4.75               | 90.12±0.92   | 80.43±0.73                      |
| 9.    | N9           | 133.8±0.15                    | 0.424±0.16                  | -18.6               | 87.34±0.26   | 73.69±0.73                      |
| 10.   | N10          | 144.5±0.13                    | 0.393±0.13                  | -17.4               | 89.45±0.71   | 74.37±0.76                      |

Mean of three observation±SD. (n=3)
Fourier transforms infrared spectroscopy (FT-IR)

FT-IR spectroscopy is one of the best techniques to evaluate the chemical stability of the encapsulated drug inside the nanosuspension. Fig. 5, 6, 7, 8 shows the FT-IR spectra of free NAR, soya lecithin, TPGS and NARNS. FT-IR spectra confirmed the successful conjugation between NAR and soya lecithin with TPGS at ~2918.40 (CH$_2$ symmetric stretching) and ~1707.27 cm$^{-1}$ (C=O carbonyl stretching) in NAR-loaded soya lecithin nanosuspension. Free NAR showed the characteristic bands due to the presence of different functional groups. A band appearing at~2918.40 cm$^{-1}$ is due to CH$_2$ asymmetric stretching vibrations while the peak observed at~1629.60 cm$^{-1}$ is due to C=O stretching respectively. These distinctive bands of free NAR are also present in NARNS, which indicates the chemical stability of NAR in nanosuspensions [42, 43].

Drug entrapment efficiency

The Percentage drug entrapment efficiency of all the formulations was calculated, and the results were tabulated in Table 2. The drug entrapment efficiency of N2 and N4 was high when compared to other formulations. This may be due to the presence of optimum polymer and TPGS concentrations, comparing the formulations N1, N3, N5, N6, N7, N8, N9, and N10. It is clear that increase in polymer concentration increased the drug entrapment efficiency. Table 2 shows the drug entrapment efficiency of a different formulation of NARNS. The concentration of the stabilizer used is the most effective factor on entrapment efficiency, and this agrees with that obtained by Patil et al. who formulate spray dried chitosan nanoparticles containing doxorubicin [44].

Saturation solubility of freeze-drying nanosuspension

The poor solubility of NAR that determined is in agreement with published researches as shown in Table 3, also the results showed that an increase in pH resulted in an increase in the solubility of NAR as showing in the fig. this is because it is an acidic drug (pKa = 7.91). It was observed that the solubility of prepared NARNS has been increased to 6.1±0.2 folds in pH 1.2 and to 7.5±0.4 folds in pH 7.4 due to the formation of stabilized nanosuspensions and it is shown in fig. 9.

In vitro drug release

In vitro, drug release profiles of NAR and NARNS are shown in fig. 10 A and 10. B. The release of NAR and the NARNS of the selected formulation were higher than the release profile of the pure drug in 60 min. The % CDR of the selected formula N2 was more than 90% in twelve h in both 0.1 N HCl and phosphate buffer pH 7.4 media as compared to less than 37.95 % and 24.82 % of NAR in the same media respectively. This will indicate that the dissolution rate of the NARNS is enhanced. Factors that contributing to a fast release was large surface area due to small particle size, high diffusion coefficient (small molecular size), low matrix viscosity and short diffusion distance of the drug [45].
**In vitro permeability studies**

The *in vitro* permeability study was carried out using Franz Diffusion Cell. After 1 h of diffusion, 97.13% (N2), of the drug was diffused from the lyophilize nanosuspension, while for NAR, the diffusion was found to be 26.27% respectively. Thus, the amount of the drug diffused through the nitrocellulose membrane has doubled when it is given to the form of a nanosuspension. It can be clearly seen that the permeation of the drug from lyophilized NARNS is much faster than the NAR. The enhanced diffusion may be explained in terms of the huge specific surface area of the nanosuspension droplets and improved permeation of the naringenin because of the presence of a surfactant, which reduces the interfacial tension of formulation [46]. The results are shown in fig. 11.

**Scanning electron microscope**

SEM was carried out to study the surface morphology of particles. It was found that NARNS revealed a smooth texture (fig 12). The SEM picture of NAR particles was found abundantly with larger particle size when compared to NARNS. Thus, soya lecithin, polaxamer-407, polaxamer 188, HPMC and Tween-80 produced better surface characteristics. The surface structure of nanosuspension in the SEM of N2 appeared good in shape. This micrograph was in agreement with those measured by particle size distribution [47].

Fig. 10B: Effect of NAR concentration and its NARNS in Phosphate buffer pH 7.4, mean of three observation±SD (n=3)

Fig. 11: Comparative permeability studies of NAR and NARNS in phosphate buffer (pH 7.4), mean of three observations±SD. (n=3)

Fig. 12(a): SEM of NAR, 13(b): SEM of Nar-Soya lecithin, 13(c): SEM of Nar-HPMC 13(d): SEM of Nar-polaxamer 188 13(e): SEM of Nar-polaxamer 407 13(f): SEM of Nar-Tween-80
Powder X-ray diffraction analysis (P-XRD)

A powder X-ray diffraction method is useful tools in identifying the physical nature of the particles. Powder x-ray diffraction patterns of free NAR, polymers and NARNs are present in fig. (13). Free NAR has displayed the characteristic crystalline peaks of 2θ of 10.83°, 11.49°, 15.75°, 17.27°, 18.07°, 20.35°, 23.73°, 25.37°, 27.71°. However, NARNs has not shown any such crystalline peaks. This absence of detectable crystalline domains of NAR in nanosuspension clearly indicates that NARNs is in amorphous or disordered crystalline phase or in the solid solution state [48].

Fig. 13(a): P-XRD of NAR, (b): P-XRD of Soya lecithin, (c): P-XRD of polaxamer-407, (d): P-XRD of Polaxamer-188, (e): P-XRD of HPMC, (f): P-XRD of Nar-Soya lecithin, (g): P-XRD of NAR-Polaxamer-407, (h): P-XRD of NAR-Polaxamer-188, (i): P-XRD of NAR-HPMC

Fig. 14: a: DSC of NAR, (b): DSC of soya lecithin, (c): DSC of polaxamer-407, (d): DSC of polaxamer-188, (e): DSC of HPMC, (f): DSC of Nar-Soya lecithin, (g): DSC of NAR-polaxamer-407, (h): DSC of NAR-polaxamer-188, (i): DSC of NAR-HPMC
Thermal analysis

DSC was used to elucidate the physical state of the drug within the system. To investigate the molecular state of the drug, DSC study was carried out. The DSC curves of NAR and lyophilized NARNS were recorded. Fig. 14 Shows DSC thermo grams of free NAR, stabilizers and NARNS. Free NAR exhibited a melting endothermic peak around at 250 °C indicating the crystalline nature of the drug. However, NARNS showed broad melting peak indicating the absence of crystalline. Nature of the thermo gram is totally changed, and the sharp peaks are shifted; the peaks of NAR have changed to broad peaks with reduction of the height of each peak. These changes indicate that the dehydration of NAR and change as the particle size giving a more amorphous type as the product this may help in increasing the dissolution rate of NARNS. Lyophilized NARNS were molecularly dispersed in an amorphous form [49, 50].

Stability studies

The promising formulation (N2) was subjected to short-term accelerated stability study by storing the formulations at high-density polyethylene bottles and stored at 4±1 °C/Ambient, 25±2 °C/60±5 % RH %, 40±2°C/75±5 % RH for 90 d. After 3 mo, the formulation was again analyzed for drug content. The data for stability studies revealed that there was no considerable difference s in drug content. The Percentage of drug content data is given in table 5.

Table 5: Stability studies of selected NARNS

| Formulation | Storage temperature condition | Initial drug content (%) | Drug content after 90 d (%) |
|-------------|-----------------------------|--------------------------|----------------------------|
| N2          | 4 °C                        | 99.52±0.13               | 99.1±0.41                  |
|             | Room temperature            | 99.0±0.91                | 99.8±0.11                  |
|             | 40 °C                       |                          |                            |

Mean of three observation:SD. (n=3)

Hemocompatibility assay

Erythrocyte hemolysis test for the formulated drug was conducted. If the hemolysis occurs, the oxyhemoglobin can drain out, and the amount of oxyhemoglobin is linear to the number of blood cells hemolyze. In the study, the rate of erythrocyte hemolysis of distilled water was set as 100% and physiological saline as 0%. The rate of erythrocyte hemolysis of formulated drug (NF2) dramatically decreased under the current experimental conditions. In general, the hemolysis % was not allowed to be higher than 5% for injection.

The rates of erythrocytes hemolysis for 500–390 µg/ml were less of the formulated drug. It demonstrated that the nanosuspension formulation could reduce the damage to erythrocyte membrane effectively, which made this preparation amenable to i. v. injection and circumvented the problem of poor solubility.

Table 6: Whole blood cell lysis

| S. No. | Concentration (µg/ml) | % hemolysis |
|--------|-----------------------|-------------|
| 1      | 500                   | 3.4±2.6     * |
| 2      | 250                   | 2.3±0.7     * |
| 3      | 125                   | 2.2±0.6     * |
| 4      | 62.5                  | 1.3±0.9     * |
| 5      | 31.25                 | 1.1±0.9     * |
| 6      | 15.62                 | 0.9±1.1     * |
| 7      | 7.81                  | 0.6±0.9     * |
| 8      | 3.90                  | 0.4±0.8     * |

* p < 0.05: % Hemolysis of selected formulation (NF2) using Student’s t-test. (n=3)

CONCLUSION

NAR nanosuspension was successfully prepared by high-pressure homogenization technique. This method of manufacturing was found to be simple and has scale-up feasibility. The nanosuspension was converted into dry powder by lyophilization in order to increase its stability. The increase in drug dissolution rate and solubility can be expected to have a significant impact on the oral bioavailability of the drug. The in vitro intestinal permeability results showed that the drug diffusion across the intestinal membrane from the NARNS is significantly higher than the NAR suspension. DSC thermo gram and P-XRD diffractograms confirmed that the crystalline was converted into amorphous nature after high-pressure homogenization and lyophilization process. Using SEM, it was found that NARNS revealed a smooth texture. The lyophilized NARNS was found to be stable when stored under refrigerated conditions. The hemocompatibility assessment results suggesting the formulated nanosuspension might be a good choice for intravenous administration of poorly soluble NAR. These observations lead us to the conclusion that nanosuspensions seem to be a promising drug delivery system, which can provide an effective and practical solution to the problem of NAR with low aqueous solubility and poor systemic bioavailability. Hence, these results suggest that the NARNS are highly promising cancer drug carrier system with interesting anticancer properties of NAR.

CONFLICT OF INTERESTS

Declared none

REFERENCES

1. Assi M, Usta J, Mounimine Y, Aboul-Ela M, EL Lakanay A. Phytochemical study and the antiproliferative activity of inula vulgaris species grown in lebanon. Int J Pharm Pharm Sci 2017;9:75-83.
2. Narain JP, Garg R, Eric A. Non-communicable diseases in the south-east Asia region: burden, strategies and opportunities. Natl Med J India 2011;24:280-7.
3. Thun MJ, DeLancey J0, Center MM, Jemal A, Ward EM. The global burden of cancer: priorities for prevention. Carcinogenesis 2010;31:100-10.
4. Moorhi C, Manavalan R, Kathiresan K. Nanotherapeutics to overcome conventional cancer chemotherapy limitations. J Pharm Pharm Sci 2011;14:67-77.
5. Brewer E, Coleman J, Lowman A. Emerging technologies of polymeric nanoparticles in cancer drug delivery. J Nanomater 2011;1:1-10. http://dx.doi.org/10.1155/2011/408675
6. Hollman PCH, Katan MB. Dietary flavonoids: intake, health effects and bioavailability. Food Chem Toxicol 1999;37:937-42.
7. Cohen J, Kristal A, Stanford J. Fruit and vegetable intakes and prostate cancer risk. J Natl Cancer Inst 2000;92:61–8.
8. Birt DF, Hendrich S, Wang W. Dietary agents in cancer prevention: flavonoids and isoflavonoids. Pharmacol Ther 2001;90:157-77.
9. Kris-Etherton PM, Hecker KD, Bonanome A, Coval SM, Binkoski AE, Hilpert RF, Griel AE, et al. Bioactive compounds in foods: their role in the prevention of cardiovascular disease and cancer. Am J Med 2001;113:71-88.
10. Verhoeven ME, Bovy A, Collins G, Muis S, Robinson S, Collier S, et al. Increasing antioxidant levels in tomatoes through modification of the flavonoids biosynthetic pathway. J Exp Bot 2002;53:2099–106.

11. Bagianesi R, Salucci M, Leonardi C, Ferracane R, Cattiga G, Azzini E, et al. Effect of domestic cooking on human bioavailability of naringenin, chlorogenic acid, lycopene and beta-carotene in cherry tomatoes. Eur J Nutr 2004;43:360-6.

12. Kawai S, Tomono Y, Katase E, Ogawa K, Yano M. Quantitation of flavonoids constituents in citrus fruits. J Agric Food Chem 1999;47:3557–65.

13. Friedoofar HR, McGrath DR, Spiegelman AD. The variable effect on proliferation of a colon cancer cell line by citrus fruit flavonoid naringenin. Colorectal Disease 2002;5:149–52.

14. Virgili F, Accorcia F, Ambra R, Rina A, Totta P, Marino M. Nutritional flavonoids modulate estrogen receptor a signaling. J Nutr Biochem 2003;14:415–6.

15. Monica Kristiani, Siamindari, Ronny Martien, Hilda Ismail, Agustinus Yuswantoro. Cytotoxic activity of acidic ribosome inactivating proteins mirabilis Jalapa L. (Rip M)-chitosan nanoparticles formulated with low-chain chitosan and low-methylated pectin. Int J Pharm Pharm Sci 2017;9:139-45.

16. Gandhi S, Mittal P, Pahade A, Rege S. Development and formulation and its pharmacokinetics of metronidazole. Int J Pharm Pharm Sci 2017;9:1667-72.

17. Azzini E, Bugianesi R, Salucci M, Leonardi C, Ferracane R, Catala G, et al. Modification of the flavonoids biosynthetic pathway. J Exp Botany 2013;413:237-44.

18. Rajabahadur M, Zia H, Nues A, Lee C. Mechanistic study of solubility enhancement of nifedipine using vitamin E TPGS or solutol HS-15. Drug Delivery 2006;13:201–6.

19. Helgason T, Awd TS, Kristbergsson K, Mcclements D, Weiss J. Effect of surfactant surface coverage on formation of solid lipid nanoparticles (SLN). J Colloid Interface Sci 2009;334:75-81.

20. Van Erdenbrugh B, Vermeul J, Martens JA, Froyen L, Van Humbeeck J, Augustijns P. A screening study of surface stabilization during the production of drug nanocrystals. J Pharm Sci 2009;98:2091–103.

21. Merisco-Liversidge E, Sarpotdar P, Bruno J, Haji S, Wei L, Peltier N. Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs. Pharm Res 1996;13:272-8.

22. Muller RH, Jacobs C, Kayser O. Nanosuspension as particulate drug formulations in therapy rationale for development and what we can expect for the future. Adv Drug Delivery Rev 2001;47:3–19.

23. Sahu SK, Mallick SK, Santra S, Maiti TK, Ghosh SK, Pramanik P. In vitro evaluation of folic acid modified carboxymethyl chitosan nanoparticles loaded with doxorubicin for targeted delivery. J Mater Sci Med 2010;21:1587-97.

24. Misra R, Sahoo SK. Intracellular trafficking of nuclear localization signal conjugated nanoparticles for cancer therapy. Eur J Pharm Biopharm 2010;75:152-63.

25. Potli P, Bhoskar M. Optimization and evaluation of spray dried chitosan nanoparticles containing doxorubicin. Int J Pharm 2012;415:279-86.

26. Dixit P, Jain DK, Dumbwani J. Standardization of an ex vivo method for determination of intestinal permeability of drugs using everted rat intestine apparatus. J Pharmaco Toxicol Methods 2012;65:33-7.

27. Mou D, Chen H, Wang J, Xu H, Yang X. Potent dried drug nanosuspensions for oral bioavailability enhancement of poorly soluble drugs with pH-dependent solubility. Int J Pharm 2011;413:237-44.

28. Malapati A, Murthy P. Solubility and dissolution rate enhancement of efavirenz by inclusion complexation and liquid anti-solvent precipitation technique. J Chem Pharm Res 2014;6:109-106.

29. Naguib YW, Rodriguez BL, Li X, Hursting SD, Williams RO, Cui Z. Solid lipid nanoparticle formulations of docetaxel prepared with high melting point triglycerides in vitro and in vivo evaluation. Mol Pharm 2014;11:1239-49.

30. Li J, Guo X, Liu Z. Preparation and evaluation of charged solid lipid nanoparticles of tetradecanol for ocular drug delivery system: pharmacokinetics, cytotoxicity and cellular uptake studies. Drug Dev Ind Pharm 2014;40:980–7.
51. Kim CK, Kim JH, Park KM, Oh KH, Oh U, Hwang SJ. Preparation and evaluation of a titrated extract of centella asiatica injection in the form of an extemporaneous micellar solution. Int J Pharm 1997;146:63–70.

52. Xiong R, Lu W, Li J, Wang P, Xu R, Chen T. Preparation and characterization of intravenously injectable nimodipine nanosuspension. Int J Pharm 2008;350:338-43.